Elixiron Immunotherapeutics Inc. is pleased to announce that on August 30, 2024, a Site Initiation Visit will be held at the Department of Neurology at Taipei Veterans General Hospital to officially launch a Phase 2 clinical trial of its innovative drug, EI-1071. This trial aims to evaluate the effect of EI-1071 on neuroinflammation in the brains of patients with Alzheimer’s disease, while also further studying its safety and tolerability.
EI-1071 is a small-molecule drug that potently and selectively inhibits the colony-stimulating factor-1 receptor (CSF-1R). Preclinical studies have demonstrated that EI-1071 can effectively penetrate the blood-brain barrier, significantly reduce microglial activation in the brain, and has the potential to improve memory impairment.
This Phase 2 clinical trial is an open-label, exploratory, proof-of-concept study that will focus on Alzheimer’s disease patients. The trial will assess the effects of EI-1071 on neuroinflammation using PET/MR imaging and selected brain biomarkers. Secondary objectives include evaluating the drug’s safety, tolerability, and exposure. The trial will be led by Dr. Jong-Ling Fuh, Deputy Chief of Department of Neurology at Taipei Veterans General Hospital.
Elixiron Immunotherapeutics is a biotech company specializing in the development of innovative immunotherapies, with its R&D platform based in Taipei. The company is dedicated to advancing transformative medicines, leveraging its deep expertise in immunology and drug discovery to bring two potentially first-in-class immunotherapies into clinical development. EI-1071, the study drug in this trial, has twice been awarded the prestigious “Part-the-Cloud” grant from the Alzheimer’s Association, highlighting its therapeutic potential for Alzheimer’s disease and other neurodegenerative conditions.
Elixiron Immunotherapeutics will continue to drive the development of cutting-edge technologies and innovative applications on a global scale, constantly strengthening its core competitiveness in the field of novel immunotherapies.
